natgillin/translations-raw huggingface dataset:
The capsule of claim 12 wherein the disintegrant is one of croscarmellose sodium, carboxymethyl cellulose, sodium starch glycolate, crospovidone or combinations thereof. 
Kapsula u skladu s patentnim zahtjevom 12 ili patentnim zahtjevom 13, naznačena time što se sredstvo za raspadanje sastoji od kroskarmeloza-natrija, karboksimetil-celuloze, natrijeva škrob glikolata, krospovidona ili kombinacija navedenog.
Cy1 is optionally further substituted by one to three independent occurrences of R6, wherein each occurrence of R6 is independently selected from —ORB, C1-3aliphatic, or halo. 
Cy! je izborno dalje supstituiran sa jednim do tri nezavisna R", pri čemu je svaki R* nezavisno izabran od -OR?, CL alifatika ili halo.
a nucleic acid encoding a fusion protein between an essential protein and a destabilizing protein, wherein the essential protein is selected from the group consisting of IE1/2, UL51, UL52, UL79 and UL84. The conditional replication defective CMV of embodiment 1, wherein the destabilizing protein is either FKBP or an FKBP derivative, wherein the FKBP derivative is FKBP comprising one or more amino acid substitutions selected from the group consisting of: F15S, V24A, H25R, F36V, E60G, M66T, R71G, D100G, D100N, E102G, K105I and L106P. 
(b) nukleinsku kiselinu koja kodira fuzijski protein između esencijalnog proteina i destabilizirajućeg proteina, pri čemu je esencijalni protein izabran iz grupe koja se sastoji od IE1/2, ULS51, UL52, UL79 1 UL84, pri čemu, destabilizirajući protein je FK506-vezujući protein (FKBP) ili FKBP derivat, pri čemu, FKBP derivat je FKBP koji sadrži jednu ili više aminokiselinskih supstitucija izabranih iz grupe koja se sastoji od: F15S, V24A, H25R, F36V, E60G, M66T, R71G, D100G, D100N, E102G, K1051I 1 L106P, i pri čemu divlji tip esencijalnog proteina nije više prisutan.
In another preferred embodiment the substituted trisaccharide core is derived from raffinose, melezitose or maltotriose and comprises one or two anionic groups, such as a sulphate ester or a phosphate ester group, and ten or nine, respectively, identical fatty acid ester groups per substituted trisaccharide. Most preferably the fatty acid ester is the ester of lauric acid. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačena time što se supstituiranu trisaharidnu jezgru izvodi iz rafinoze, melezitoze ili maltotrioze, te što trisaharidna jezgra sadrži jednu sulfatnu ili fosfatnu estersku skupinu i deset istovjetnih esterskih skupina masnih kiselina po supstituiranom trisaharidu ili dvije sulfatne ili fosfatne esterske skupine i devet istovjetnih esterskih skupina masnih kiselina po supstituiranom trisaharidu.
continuously feeding a solution of a cyclic tertiary amine in a suitable solvent or mixture of solvents and an alkylating agent, optionally dissolved in a suitable solvent or mixture of solvents, into a continuous-flow reactor; 
kontinuirano napajanje otopine cikličkog tercijarnog amina u pogodnoj otopini ili smjesi otopine i sredstva za alkilaciju, otopljenog u pogodnoj otopini ili smjesi otopine koje su aprotonske otopine odabrane od amida, nitrila i sulfoksida, u reaktor s kontinuiranim protokom;
Xaa5 is L-Thr, D-Thr, Ile, Val, Gly, a dipeptide comprising Thr-Asn or Thr-Ala, or a tripeptide comprising Thr-Ala-Asn, wherein a carboxy terminal -OH of any of the L-Thr, D-Thr, Ile, Val, Gly or Asn optionally is replaced by -NH2; the method comprising synthesizing the peptide by condensation of the amino acid residues or analogs thereof, or expressing a polynucleotide encoding the peptide. 
Xaa5 je L-Thr, D-Thr, Ile, Val, Gly, dipeptid Thr-Asn ili Thr-Ala ili tripeptid Thr-Ala-Asn, gdje je na karboksi krajnjem -OH bilo koji od L-Thr, D-Thr, Ile, Val, Gly ili Asn po izboru zamijenjen s -NH2; i dva ostatka Cys povezana su disulfidnom vezom.
reacting Compound 9 with an acid to produce Compound 10. 
reakciju spoja 9 sa kiselinom da se proizvede spoj 10.
The puller assembly of claim 7 wherein a first tooth of said teeth which is closest to said second axial end extends farther radially inward than a second tooth that is closer to said first axial end. 
Sklop ekstraktora prema patentnom zahtjevu 7, naznačen time, što se prvi zubac (106) predmetnih zubaca koji je najbliži predmetnom drugom aksijalnom kraju (43) proteže dalje radijalno prema unutra od drugog zupca (103105) koji je bliže predmetnom prvom aksijalnom kraju (42).
optionally substituted heterocyclylakenyl; optionally substituted heterocyclylalkynyl; optionally substituted cycloalkoxy, cycloalkylalkyloxy, heterocyclylalkoxy or heterocyclyloxy; 
opcijski supstituiran heterociklilalkenil; opcijski supstituiran heterociklilalkinil; opcijski supstituiran cikloalkoksi, cikloalkilalkiloksi, heterociklilalkoksi ili heterocikliloksi;
By that, it is meant that the fuel element is not purposely impregnated or mixed with substantial amounts of volatile organic materials, such as volatile aerosol forming or flavoring agents, which could degrade in the burning fuel. 
Pod tim se podrazumjeva da gorivi element nije namjerno impregniran ili pomješan sa suštinskim količinama isparljivih organskih materijala, kao što su sredstva za formiranje isparljivih aerosola ili mirisna sredstva, koja bi mogla degradirati gorivo koje izgara.
the pharmaceutical composition comprises polysorbate-80; 
(v) farmaceutski sastav obuhvaća polisorbat-80;
A method for the packaging of kernels of corn for popping inside a microwave oven characterised in that the method comprises a stage in which kernels of corn, a distribution agent free of oil or fat, and a flavouring agent are dispensed separately into a microwaveable popcorn package through an arrangement of independent discharge openings, adapted to-provide respectively, the kernels of corn, distribution agent, and flavouring agent, and a stage for the mixture of food additives selected from among an emulsifier and a lecithin, wherein any said lecithin is added in an amount to provide less than 0.13% by weight of the microwaveable package and wherein no oils or fat are found in the composition. 
HR P20181674 T1 PATENTNI ZAHTJEVI Postupak pakiranja zrna za kokice, namijenjenim pripravi kokica u mikrovalnim pećima; naznačen time što se pakiranje provodi bez prisutnosti masti ili ulja, te što se postupak sastoji u koraku razdjeljivanja zrna za kokice sredstvom za raspodjeljivanje, koje je emulzija ili smjesa najmanje dva emulgirajuća ili emulgentna prehrambena dodatka, uz dodatak sredstva za aromatiziranje u pakiranje kojeg se može peći mikrovalovima kroz neovisne otvore za pražnjenje, prilagođene za dodavanje odnosno doziranje, na zrna za kokice, sredstva za raspodjeljivanje i sredstva za aromatiziranje.
Alkyl, alkenyl, and alkynyl groups may be substituted. 
(7) supstituirani i nesupstituirani alkil, (8) -COR2, i
The starting material: 4-amino-3-trifluoromethyl-benzoic acid was prepared according to literature procedures: Krüger et al. Arzneim.Forsch.; 34; 11a; 1984; 1612-1624. 
Ulazni materijal: 4-amino-3-trifluorometil-benzojeva kiselina se pripravi prema postupcima danim u literaturi: Kriiger et al. Arzneim.
The therapeutic agent for use according to claim 11, wherein the disease with a highly expressed human CDH3 is selected from breast cancer, lung cancer, colon cancer, or pancreatic cancer. 
Terapijsko sredstvo, namijenjeno upotrebi u skladu s patentnim zahtjevom 11, naznačeno time što se bolest kod koje se visoko eksprimira ljudski CDH3 bira između raka dojke, raka pluća, raka debelog crijeva ili raka gušterače.
admixing up to about 30 weight percent of a crystalline or semicrystalline polymer to provide a mixture comprising at least 70 weight percent aliphatic polycarbonate; 
(b) miješanje do oko 30 postotnih težinskih udjela polukristalnog polimera radi dobivanja smjese koja sadržava najmanje 70 postotnih težinskih udjela alifatskog polikarbonata;
A compound according to claim 1, that is: 
Spoj u skladu sa patentnim zahtjevom 1, koje je:
Use as claimed in any of claims 1 to 16, combination as claimed in claim 17, composition as claimed in claim 18, compound as claimed in claim 19 or product as claimed in claim 20, wherein the bacterial infection is an infection with Staphylococci, Enterococci or Streptococci. 
Uporaba prema bilo kojem zahtjevu od 1 do 16, kombinacije prema zahtjevu 17, pripravka prema zahtjevu 18, spoja prema zahtjevu 19 ili proizvoda prema zahtjevu 20, naznačena time da bakterijska infekcija je infekcija sa bakterijom Staphilococci, Enterococci ili Streptococci.
In a preferred embodiment the counter further comprises a coupling mechanism for releasably coupling said first ring member to said second ring member, to allow said first and second ring members to rotate cooperatively when coupled and to allow independent rotating of said first ring member when not coupled. 
Brojač kao što je navedeno u zahtjevu 1 dalje sadržeći mehanizam sparivanja (700) za odvojivo sparivanje navedenog prvog prstenastog elementa (201) s navedenim drugim prstenastim elementom (202, 1510), kako bi se omogućilo navedenim prvom i drugom prstenastom elementu da kooperativno rotiraju kad spareni te kako bi se omogućilo samostalno rotiranje navedenog prvog prstenastog elementa kad nije sparen.
The isolated DNA according to claim 9 in which the DNA sequence encoding the heavy chain comprises the sequence given in SEQ ID NO:12 or SEQ ID NO:15 or nucleotides 58-2008 of SEQ ID NO:15. 
Stanica domaćin prema zahtjevu 8, naznačena time da DNK sekvenca koja kodira teški lanac sadrži sekvencu datu u SEQ ID NO: 12ili SEQ ID NO: 15 ili nukleotide 58-2008 sekvence SEQ ID NO: 15.
Elution was started with 0.075 M ammonium acetate pH 9.0±0.1, conductivity 7.6±0.5 mS/cm. r-hIL-18BP started eluting as a main peak after about 0.5 BV from the start. 3-5 BV of the main peak were collected, the main peak starting when the on-line OD steeply increased. 
Elucija je započeta s 0.075 M amonij acetatom, pH 9.0 +0.1, i provodljivosti od 7.6+0.5 mS/cm. r-hIL-18BP se počeo eluirati kao glavni pik nakon oko 0.5 BV iz 3-5 BV glavnog pika su bili sakupljeni, a glavni pik počinje kada se procesni OD oštro povećava.
The composition for use according to any one of the preceding claims, wherein the subject is administered a high initial dose of the at least one C1 esterase inhibitor, followed by lower maintenance doses, optionally wherein the high initial dose is at least 1.5, 2, 3, 4, or 5 times the subsequent doses, and/or the high initial dose is administered intravenously and the at least one C1 esterase inhibitor is subsequently administered subcutaneously. 
Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time da se subjektu daje visoka početna doza najmanje jednog inhibitora C1 esteraze, nakon čega slijede manje doze za održavanje, pri čemu je po potrebi visoka početna doza najmanje 1,5, 2, 3, 4, 1li 5 puta naknadnih doza, i/ili se visoka početna doza daje intravenozno i nakon toga se najmanje jedan inhibitor C1 esteraze daje potkožno.
The present invention encompasses the polymorph isolated in pure form or when admixed with other materials, for example the known forms of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline or any other material. 
Ovaj izum obuhvaća polimorf izdvojen u čistom obliku ili u smjesi s drugim materijalima, primjerice poznatim oblicima 3-fenilsulfonil-8-piperazin-1-ilkinolina, ili bilo kojim drugim materijalom.
The calorimeter cell was closed and a flow of nitrogen was passed through the cell. 
Kalorimetarska ćelija je zatvorena i pušten je protok dušika kroz nju.
The method of any of items 22-26, wherein said genetic variant of the TOMM40 gene is a variant selected from the group consisting of: rs10524523, rs10602329, and DIP3. 
Liječenje s učinkovitom količinom djelotvornog sredstva protiv Alzheimerove bolesti, za uporabu prema bilo kojem zahtjevu od 4 do 8, naznačeno time, da genetička varijanta od TOMM40 gena je rs10524523.
At the beginning of the investigation, each tablet was placed in a 600 ml portion of artificial gastric juice, pH 1.2. 
Na početku ispitivanja svaka je tableta stavljena u po 600 ml umjetnog želučanog soka s pH 1,2.
A pesticide against parasite on animal, containing the anthranilamide compound or its salt as defined in Claim 1, as an active ingredient. 
Pesticid, naznačen time, da kao djelatni sastojak sadrži spoj antranilamida ili sol istog kako je definirano u patentnom zahtjevu 1.
A peptide according to any one of claims 1 to 3 or an activated cytotoxic T lymphocyte according to claim 10 for use in the treatment of cancer. 
Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 5, stanica u skladu s patentnim zahtjevom 8 ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 11 za upotrebu u liječenju karcinoma.
A method for making the absorbent composition according to any one of claims 1 to 5 comprising the steps of: forming a composition comprising a particulate copper compound capable of forming copper sulphide, a particulate support material selected from an alumina, hydrated alumina, titania, zirconia, silica or aluminosilicate, or a mixture of two or more of these, and one or more binders comprising a first binder and a second binder, wherein the first binder is a calcium aluminate cement binder and the second binder is a high aspect ratio aluminosilicate clay binder having an aspect ratio >2, 
dobivanja mješavine koja sadrži partikularni bakreni spoj koji može dati bakreni sulfid, partikularni nosivi materijal, kojeg se bira između aluminijevog oksida, hidratiranog aluminijevog oksida, titanijevog dioksida, cirkonijevog dioksida, silicijevog dioksida ili alumosilikata, ili smjesu iz dva ili više od navedenih, te jedno ili više veziva koja uključuju prvo vezivo i drugo vezivo, gdje je prvo vezivo kalcijev aluminatni cement kao vezivo, a drugo je vezivo alumosilikatna glina visokog omjera dimenzija kao vezivo s omjerom dimenzija >2, ii) oblikovanja mješavine kako bi se dobilo preteču apsorbensa, iii) sušenju materijala koji je preteča apsorbensa, i iv) sulfidiranju preteče kako bi se dobilo apsorbens.
The method of claim 1, wherein the sample comprises a biological sample, wherein the biological sample comprises material selected from the group consisting of body fluids, mucus secretions, saliva, blood, whole blood, plasma, and serum. 
Postupak prema zahtjevu 7, naznačen time što uzorak je biološki uzorak, te biološki uzorak sadrži materijal odabran iz skupine koja se sastoji od tjelesnih tekućina, sekreta sluzi, sline, krvi, pune krvi, plazme, seruma, staklaste tekućine, i tekućine očne vodice.
In a third aspect of the invention, there is provided a pharmaceutical composition comprising a compound according to the invention in its first or second aspects. 
U trećem aspektu izuma, donosi se farmaceutski pripravak koji sadrži spoj prema izumu u njegovom prvom ili drugom aspektu.
the polypeptide is isolated from the cell culture medium, wherein the isolated polypeptide is concentrated to provide a composition comprising a polypeptide at a concentration of at least 100 mg/ml and wherein the composition has a color reference standard value selected from any one of B4-B9, BY4-BY7, Y4-Y7, GY4-GY7 and R4-R7 according to the European Pharmacopoeia color standards, European Pharmacopoeia, 2008, 7th Edition, Page 22. 
Cc) = polipeptid je izoliran iz medija stanične kulture, gdje je izolirani polipeptid koncentriran za osiguravanje pripravka koji obuhvaća polipeptid u koncentraciji od najmanje 100 mg/ml, te time, da pripravak ima standardnu vrijednost referentne boje odabrane od bilo koje iz skupine od B4-B9, BY4-BY7, Y4-Y7, GYA4- GY7 i R4-R7 u skladu sa standardima boja za Europsku farmakopeju, Europska farmakopeja, 2008, 7. izdanje, stranica 22.
A recombinant molecule or a set of at least two nucleic acid molecules according to claim 4, wherein said nucleic acid sequence encoding E1A protein and a nucleic acid sequence encoding at least one E1B protein are separated by at least 10 kb. 
Rekombinantna molekula ili skup od barem dvije molekule nuklemske kiseline prema zahtjevu 4, naznačena time da su navedena sekvenca nukleinske kiseline koja kodira ELA protein i sekvenca nukleinske kiseline koja kodira barem jedan E1B protein odvojene sa barem 10 kb.
ii) a source for the sterilisation buffer; 
izvor za sterilizacijski pufer;
The filtrate was concentrated at reduced pressure and the second batch of suspended solid was collected by filtration. 
Filtrat se koncentrira uz smanjeni tlak 1 druga šarža suspenzirane krutine se sakupi filtriranjem.
a consumption related data element storage means (CB) comprising a plurality of storage locations (Nx, Nx+1) for storing data elements related to the consumption of said utilities and at least indicative of the consumption of said utilities, measured at the time of storing a respective one of said data elements; 
- sredstva za pohranu podatkovnih elemenata vezanih uz potrošnju (CB) koje se sastoji od velikog broja lokacija za pohranu (Nx, Nx+1) za pohranu podatkovnog elementa vezano uz potrošnju navedenih komunalnih usluga za koju je indikativna i koja je izmjerena u vrijeme pohrane dotičnog podatkovnog elementa;
The example, the aerosol forming substance may be applied full strength or in a dilute solution by dipping, spraying, vapor deposition, or similar techniques. 
Na primjer, supstanca za formiranje aerosola može se primjeniti punom jačinom ili u razblaženoj otopini uranjanjem, prskanjem, deponiranjem pare ili sličnim tehnikama.
control condition 6, during the charging of the universal rechargeable battery, the lithium-ion battery charging/discharging control circuit detects a temperature of the lithium-ion battery, and cutoffs the charging of the lithium-ion battery when the temperature of the lithium-ion battery raises to a charging upper threshold temperature TCH and restores the charging of the lithium-ion battery when the temperature of the lithium-ion battery decreases to be lower than TCH-AT1, wherein TCH is a preset charging upper threshold temperature of the lithium-ion battery, and AT1 is a preset backlash temperature corresponding to a backlash voltage of the TCH detection threshold; 
kontrolni uvjet 6, tijekom punjenja univerzalne punjive baterije, kontrolni krug za punjenje/pražnjenje litij-ionske baterije detektira temperaturu litij-ionske baterije, i prekida punjenje litij-ionske baterije kada temperatura litij-ionske baterije raste do gornjeg praga temperature TCH punjenja i uspostavlja punjenje litij-ionske baterije kada se temperatura litij-ionske baterije smanji da bude niža nego TCH-AT1, gdje TCH je unaprijed podešeni gornji prag temperature punjenja litij-ionske baterije, a AT1 je unaprijed podešena temperatura mrtve zone koja odgovara naponu mrtve zone TCH praga za detekciju;
The composition of claim 11 wherein said cyclodextrin is a hydroxypropyl B-cyclodextrin or sulfobutylether 3-cyclodextrin, said pharmaceutically acceptable salt is an acetate salt, and said pH adjusting agent is sodium bicarbonate. 
Sastav prema zahtjevu 11, naznačeno time da je spomenuti ciklodekstrin hidroksipropil B-ciklodekstrin ili sulfobutileter B-ciklodekstrin, a spomenuta farmaceutski prihvatljiva sol sol acetata, te spomenuti agens prilagodbe PH vrijednosti natrijev bikarbonat.
With reference to fig. 
U svezi sa sl.
The lipid compound according to claim 1, wherein X is a carboxylic acid or a derivative thereof in the form of an ester, a mono-glyceride, a 2-mono-glyceride, a diglyceride, a triglyceride, or a phospholipid. 
Lipidni spoj prema bilo kojem od prethodnih zahtjeva, pri čemu X je karboksilna kiselina ili njen derivat u obliku estera, mono-glicerida, 2-mono-glicerida, diglicerida, triglicerida ili fosfolipida.
A method according to claim 7, further comprising partially de-watering the slurry. 
Metoda u skladu s patentnim zahtjevom 7, nadalje obuhvaća korak djelomičnog odvodnjavanja mulja.
A method of receiving at least one broadcast signal having Physical Layer Pipe (PLP) data, the method comprising: 
Postupak odašiljanja barem jednog emitiranog signala s PLP podacima za prenošenje toka usluge, postupak obuhvaća: vanjsko kodiranje PLP podataka;
represents linear or branched PEG 20 kDa to 80 kDa endcapped with a methoxy-group, or a salt thereof, in combination with an inert nontoxic pharmaceutically suitable excipient, wherein the pharmaceutical composition is in a pharmaceutical form for administration by inhalation. 
R* predstavlja ravni ili razgranatni PEG 20kDa do 80kDa zaklopljen s metoksi skupinom, ili jedna od njegovih soli, njegovi solvati ili solvati njegovih soli, u kombinaciji s inertnim netoksičnim farmaceutski prikladnim ekscipijentom, pri čemu je lijek u farmaceutskom obliku za inhalaciju.
determining the moisture content of the seed; and 
(i) utvrđivanja sadržaja vlage u sjemenu; i
The compound according to claim 1 or a salt thereof, or a hydrate or a solvate thereof, wherein R27 is a group represented by the formula NR29. 
Spoj u skladu s patentnim zahtjevom 1 ili sol istog ili hidrat ili solvat istog, naznačen time, da je R27 skupina predstavljena formulom NR29.
The method of claim 32, wherein the inflammatory bowel disease is Crohn's disease. 
Spoj za upotrebu prema zahtjevu 18, pri čemu upalna bolest crijeva je Crohnova bolest.
A method of treating a neoplastic disease in a subject comprising administering to the subject a therapeutically effective amount of the compound according to claim 1 . 
Spoj koji se, sukladno patentnom zahtjevu 1, koristi kao metoda liječenja neoplastične bolesti kod pojedinca.
Use of the carbostyril derivative or a salt thereof as set forth in claim 1 or 2 for improving the descended action of donepezil or a salt thereof for treating Alzheimer's disease. 
Uporaba derivata karbostirila ili njegove soli kako je navedeno u zahtjevu 1 ili 2, te donepezila ili njegove soli naznačena time da je za pripravu lijeka za liječenje Alzheimerove bolesti.
An inoculant application system must be able to be adjusted and adapted accordingly. 
Sustav za nanošenje okulanta može biti u stanju da se podesi i odgovarajuće prilagodi.
In a further aspect a process is provided for introducing a substance into a hypodermic syringe comprising: providing a syringe having a plunger of this invention, passing a hollow needle through the plunger, introducing the substance into the vial via the needle, withdrawing the needle from the syringe and plunger, and sealing the small residual puncture hole in the plunger by heat sealing, e.g. using a focused laser beam as described above. 
U jednom daljnje aspektu predviđen je postupak za uvođenje tvari u potkožnu špricu, koji postupak sadržava: dobavljanje šprice koja ima klip iz ovog izuma, prolaženje šuplje igle kroz klip, uvođenje tvari u bočicu kroz navedenu iglu, izvlačenje igle iz šprice i iz klipa i nepropusno zatvaranje male preostale probušene rupice u klipu pomoću vrućeg nepropusnog zatvaranja, na primjer, korištenjem fokusiranog laserskog snopa kao što je to gore opisano.
dissolving a freebase of Compound 1 in a first solvent or combination of solvents to form a first solution; 
otapanju slobodne baze Spoja 1 u prvom otapalu ili kombinaciji otapala kako bi se dobilo prvu otopinu;
represents a group selected from a hydrogen atom, fluoro atom, chloro atom or methyl; 
predstavlja skupinu odabranu od atoma vodika, atoma fluora, atoma klora ili metila;
A computer-readable medium containing instructions that, when executed by a computer system, cause said computer system to implement the method according to any one of Claims 1-3. 
Računalni medij za očitavanje, naznačen time, da se sastoji od uputa koje, kada su obrađene pomoću računalnog sustava, uzrokuju da taj računalni sustav primjenjuje postupak prema zahtjevu 1 ili 2.
Permeation may also be enhanced by removing hair from the application site by, e.g. 
Prodiranje se može također poboljšati uklanjanjem dlaka s mjesta primjene, npr.
For example, such a solution has the following components at the following concentrations: to 600 g/L PEG having an average molecular weight of 2500 to 4500; to 20 g/L sodium chloride; 
(a) 350 do 600 g/l polietilen-glikola (PEG) prosječne molekulske težine od 2500 do 4500; (b) 8,0 do 20 g/I natrijevog klorida;
it is not obtained by reaction of (petro)chemicals. 
nije dobiven reakcijom (petro)kemikalija.